Date: 2016-01-18
Type of information: Nomination
Compound:
Company: Silence Therapeutics (UK)
Therapeutic area:
Type agreement: nomination
Action mechanism:
Disease:
Details: * On January 18, 2016, Silence Therapeutics, a UK-based company specialised in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases, announced the appointment of Stuart Collinson D.Phil MBA, as Non-Executive Director of the Company, with immediate effect. Silence also announces the resignation of Simon Sturge as Non-Executive Director of the Company, with immediate effect. Simon has decided to resign from the Board due to his other business commitments. Stuart will take on the role of Chair the Remuneration Committee.
Dr. Collinson has held executive and senior management positions in public and private life science companies in the US and Europe. He is a partner of Forward Ventures, a biopharmaceutical venture capital fund, Chairman and CEO of Tioga Pharmaceuticals, Inc., and Director of Arcturus Therapeutics, Inc. and Essentialis, Inc. He was Chairman, Chief Executive Officer and President of previously listed Aurora Biosciences Corp and subsequently Director of Vertex Pharmaceuticals Inc. (2001-2011). Stuart was also previously a director of several biopharmaceutical companies. He held senior management positions at GlaxoWellcome plc (now GSK) and Baxter International, and was a consultant with The Boston Consulting Group.
Financial terms:
Latest news:
